CG Oncology, Inc.
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
CGON$74.74-1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets · (unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $33,700 | $32,490 |
| Marketable securities | 1,042,542 | 709,665 |
| Inventory | 1,493 | 1,565 |
| Accounts receivable, net | 1,275 | 688 |
| Prepaid expenses and other current assets | 23,133 | 15,067 |
| Total current assets | 1,102,143 | 759,475 |
| Property and equipment, net | 15,074 | 15,596 |
| Operating lease right-of-use assets | 4,512 | 3,971 |
| Intangible assets, net | 560 | 575 |
| Goodwill | 10,297 | 10,297 |
| Other assets | 2,676 | 1,678 |
| Total assets | $1,135,262 | $791,592 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,236 | $5,714 |
| Operating lease liabilities, current portion | 1,066 | 915 |
| Accrued expenses and other current liabilities | 25,914 | 24,207 |
| Total current liabilities | 35,216 | 30,836 |
| Long-term debt | 3,000 | 3,000 |
| Operating lease liabilities, net of current portion | 3,509 | 3,106 |
| Deferred tax liability | 307 | 307 |
| Other liabilities | 1,451 | 1,741 |
| Total liabilities | 43,483 | 38,990 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value per share; 700,000,000 and 700,000,000 shares authorized as of March 31, 2026 and December 31, 2025, respectively; 88,007,761 and 80,689,128 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 9 | 8 |
| Additional paid-in capital | 1,530,948 | 1,131,570 |
| Accumulated deficit | (439,178) | (378,976) |
| Total stockholders' equity | 1,091,779 | 752,602 |
| Total liabilities and stockholders' equity | $1,135,262 | $791,592 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.